Journal
DRUG DESIGN DEVELOPMENT AND THERAPY
Volume 9, Issue -, Pages 3455-3458Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/DDDT.S86438
Keywords
interleukin-6; Castleman's disease; clinical trials
Categories
Funding
- National Natural Science Foundation of China [81170492, 81370673]
- National High Technology Research and Development Program 863 of People's Republic of China [2012AA022703]
- National Key Basic Research Program 973 of People's Republic of China [2010CB732404]
- Key Medical Projects of Jiangsu Province [BL2014078]
- Key Medical Discipline of Jiangsu Province
Ask authors/readers for more resources
Siltuximab (CNTO 328) is a promising antibody-drug conjugate targeting cytokine interleukin-6 ( IL-6). It is highly binding to IL-6 and thus neutralizing IL-6 bioactivity and promoting death of tumor cell. In this review, we mainly focus on the mechanisms, clinical studies, and adverse effect of siltuximab in the treatment of human malignancies. We also provide our recommendations for siltuximab treatment in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
